IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A ~~pharmaceutical composition for use in the treatment or prevention of diseases~~ method for treating or preventing a disease, wherein ~~where~~ the inhibition of autophosphorylation of FMS-like tyrosine kinase 3 (Flt3), ~~and/or~~ its somatic cell variant (Flt3-ITD), or a combination thereof is therapeutically or prophylactically effective, ~~which comprises~~ comprising administering a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof together with a pharmaceutically acceptable carrier, to a mammal:



(I)

wherein

X represents CH or N,

Z represents O or S,

R^1, R^2, and R^3, which may be the same or different, represent

a hydrogen atom,

hydroxyl,

halogen,

nitro,

cyano,

amino,

C_{1-6} alkyl,

C_{2-6} alkenyl,

C_{2-6} alkynyl,

C_{1-6} alkoxy,

$-(C=O)OR^C$ wherein R^C represents a hydrogen atom or C_{1-4} alkyl, or

$-(C=O)NR^dR^e$ wherein R^d and R^e, which may be the same or different, represent a hydrogen atom or C_{1-4} alkyl,

the C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and C_{1-6} alkoxy groups, which may be represented by R^1, R^2, and R^3, are optionally substituted by hydroxyl ; a halogen atom; C_{1-6} alkoxy; C_{1-6} alkylcarbonyl; carboxyl; C_{1-6} alkoxycarbonyl; $-(C=O)-NR^{10}R^{11}$ wherein R^{10} and R^{11}, which may be the same or different, represent a hydrogen atom or C_{1-4} alkyl optionally substituted by hydroxyl, or R^{10} and R^{11} may combine with a nitrogen atom attached thereto to form a saturated five- or six-membered heterocyclic group; amino in which one or two hydrogen atoms on the amino group are optionally substituted by C_{1-6} alkyl or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, and the C_{1-6} alkyl group is further optionally substituted by hydroxyl, C_{1-6} alkoxy, or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group; or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group in which the carbocyclic or heterocyclic group is optionally substituted by hydroxyl, an oxygen atom, a halogen atom, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkoxycarbonyl, or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl groups are further optionally substituted by hydroxyl,

C_{1-6} alkoxy, or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, and, when the carbocyclic or heterocyclic group is substituted by two C_{1-6} alkyl groups, the two alkyl groups may combine together to form an alkylene chain, or the carbocyclic or heterocyclic group may be a bicyclic group condensed with another saturated or unsaturated five- to seven-membered carbocyclic or heterocyclic group;

one or two hydrogen atoms on the amino group, which may be represented by R^1, R^2, and R^3, are optionally substituted by C_{1-6} alkyl which is further optionally substituted by hydroxyl or C_{1-6} alkoxy;

R^4 represents a hydrogen atom;

all of R^5, R^6, R^7, and R^8 represent a hydrogen atom, or any one or two of R^5, R^6, R^7, and R^8 represent a halogen atom, C_{1-4} alkyl, C_{1-4} alkoxy, nitro, amino, or hydroxyl with all the remaining groups representing a hydrogen atom, and

R^9 represents C_{1-4} alkyl substituted by a substituent selected from the group consisting of a saturated three- to nine-membered carbocyclic group optionally substituted by C_{1-4} alkyl, C_{1-4} alkoxy, or hydroxyl; i-propyl optionally substituted by C_{1-4} alkyl, C_{1-4} alkoxy, or hydroxyl; t-butyl optionally substituted by C_{1-4} alkyl, C_{1-4} alkoxy, or hydroxyl; C_{1-4} alkoxy; and $-NR^aR^b$ wherein R^a and R^b, which may be the same or different, represent a hydrogen atom or C_{1-4} alkyl optionally substituted by hydroxyl, or R^a and R^b may combine with a nitrogen atom attached thereto to form a saturated five- or six-membered heterocyclic group, or R^9 represents a saturated three- to nine-membered carbocyclic group optionally substituted by one to three C_{1-4} alkyl groups.

Claim 2 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 1, wherein the disease where the inhibition of autophosphorylation of Flt3, ~~and/or~~ Flt3-ITD, or a combination thereof is therapeutically or prophylactically effective is hematopoietic malignancy.

Claim 3 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 2, wherein the hematopoietic malignancy is acute myelocytic leukemia or myelodysplastic syndrome.

Claim 4 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 1, wherein the disease where the inhibition of autophosphorylation of Flt3, ~~and/or~~ Flt3-ITD, or a combination thereof is therapeutically or prophylactically effective is an immunological disease caused by abnormal proliferation of B cells, dendritic cells, or natural killer cells.

Claim 5 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 1, which is used in the treatment or prevention of diseases where the inhibition of autophosphorylation of Flt3 is therapeutically or prophylactically effective.

Claim 6 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 5, wherein the disease where the inhibition of autophosphorylation of Flt3 is therapeutically or prophylactically effective is hematopoietic malignancy.

Claim 7 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 6, wherein the hematopoietic malignancy is acute myelocytic leukemia or myelodysplastic syndrome.

Claim 8 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 5, wherein the disease where the inhibition of autophosphorylation of Flt3 is therapeutically or prophylactically effective is an immunological disease caused by abnormal proliferation of B cells, dendritic cells, or natural killer cells.

Claim 9 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 1, which is used in the treatment or prevention of diseases where the inhibition of autophosphorylation of Flt3-ITD is therapeutically or prophylactically effective.

Claim 10 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 9, wherein the disease where the inhibition of autophosphorylation of Flt3-ITD is therapeutically or prophylactically effective is hematopoietic malignancy.

Claim 11 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 10, wherein the hematopoietic malignancy is acute myelocytic leukemia or myelodysplastic syndrome.

Claim 12 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 9, wherein the disease where the inhibition of autophosphorylation of Flt3-ITD is

therapeutically or prophylactically effective is an immunological disease caused by abnormal proliferation of B cells, dendritic cells, or natural killer cells.

Claim 13 (Currently Amended): The ~~pharmaceutical composition~~ method according to ~~any one of claims 1 to 12~~ claim 1, wherein X represents CH and Z represents O.

Claim 14 (Currently Amended): The ~~pharmaceutical composition~~ method according to ~~any one of claims 1 to 13~~ claim 1, wherein R^1 represents a hydrogen atom and R^2 and R^3, which may be the same or different, represent optionally substituted C_{1-6} alkoxy.

Claim 15 (Currently Amended): The ~~pharmaceutical composition~~ method according to ~~any one of claims 1 to 14~~ claim 1, wherein R^1 represents a hydrogen atom, R^2 and R^3, which may be the same or different, represent -O-(CH_2)p-R^{12} wherein p is an integer of 0 to 6, -(CH_2)p- is optionally substituted by C_{1-6} alkyl, hydroxyl, or a halogen atom, and R^{12} represents a hydrogen atom; hydroxyl; a halogen atom; C_{1-6} alkoxy; C_{1-6} alkylcarbonyl; carboxyl; C_{1-6} alkoxycarbonyl; -(C=O)-$NR^{13}R^{14}$ wherein R^{13} and R^{14}, which may be the same or different, represent a hydrogen atom or C_{1-4} alkyl optionally substituted by hydroxyl, or R^{13} and R^{14} may combine with a nitrogen atom attached thereto to form a saturated five- or six-membered heterocyclic group; amino in which one or two hydrogen atoms on the amino group are optionally substituted by C_{1-6} alkyl or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, and the C_{1-6} alkyl group

is further optionally substituted by hydroxyl, C_{1-6} alkoxy, or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group; or a

saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group in which the carbocyclic or heterocyclic group is optionally substituted by hydroxyl, an oxygen atom, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkoxycarbonyl, or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl groups are further optionally substituted by hydroxyl, C_{1-6} alkoxy, or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, and, when the carbocyclic or heterocyclic group is substituted by two C_{1-6} alkyl groups, the two alkyl groups may combine together to form an alkylene chain, or the carbocyclic or heterocyclic group may be a bicyclic group condensed with another saturated or unsaturated five- to seven-membered carbocyclic or heterocyclic ring.

Claim 16 (Currently Amended): The ~~pharmaceutical composition~~ method according to ~~any one of claims 1 to 15~~ claim 1, wherein all of R^5, R^6, R^7, and R^8 represent a hydrogen atom; or R^6 represents a fluorine atom, and R^5, R^7, and R^8 represent a hydrogen atom; or R^5 represents a halogen atom, C_{1-4} alkyl, C_{1-4} alkoxy, nitro, or amino, and R^6, R^7, and R^8 represent a hydrogen atom; or R^5 and R^7

represent a halogen atom, C_{1-4} alkyl, C_{1-4} alkoxy, nitro, or amino, and R^6 and R^8 represent a hydrogen atom.

Claim 17 (Currently Amended): The ~~pharmaceutical composition~~ method according to ~~any one of claims 1 to 16~~ claim 1, wherein R^9 represents $-(CH_2)s-R^{51}$ wherein s is an integer of 1 to 4, and R^{51} represents a saturated three- to seven-membered carbocyclic group;

i-propyl optionally substituted by hydroxyl; t-butyl optionally substituted by hydroxyl; C_{1-4} alkoxy; or $-NR^{52}R^{53}$ wherein R^{52} and R^{53}, which may be the same or different, represent a hydrogen atom, or C_{1-4} alkyl optionally substituted by hydroxyl, or R^{52} and R^{53} may combine with a nitrogen atom attached thereto to form a saturated five- or six-membered heterocyclic group, or R^9 represents a saturated five- to seven-membered carbocyclic group optionally substituted by one to three C_{1-4} alkyl groups.

Claim 18 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 1, wherein

X represents CH or N,

Z represents O or S,

R^1, R^2, and R^3, which may be the same or different, represent

a hydrogen atom,

hydroxyl,

a halogen atom,

nitro,

amino,

C_{1-6} alkyl,

C_{2-6} alkenyl,

C_{2-6} alkynyl, or

C_{1-6} alkoxy,

the C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and C_{1-6} alkoxy groups, which may be represented by R^1, R^2, and R^3, are optionally substituted by hydroxyl; a halogen atom; C_{1-6} alkoxy; C_{1-6} alkylcarbonyl; carboxyl; C_{1-6} alkoxycarbonyl; $-(C=O)-NR^{10}R^{11}$ wherein R^{10} and

R^{11}, which may be the same or different, represent a hydrogen atom or C_{1-4} alkyl optionally substituted by hydroxyl, or R^{10} and R^{11} may combine with a nitrogen atom attached thereto to form a saturated five- or six-membered heterocyclic group; amino in which one or two hydrogen atoms on the amino group are optionally substituted by C_{1-6} alkyl or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, and the C_{1-6} alkyl group is further optionally substituted by hydroxyl, C_{1-6} alkoxy, or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group; or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group in which the carbocyclic or heterocyclic group is optionally substituted by hydroxyl, an oxygen atom, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkoxycarbonyl, or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl groups are further optionally substituted by hydroxyl, C_{1-6} alkoxy, or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, and, when the carbocyclic or heterocyclic group is substituted by two C_{1-6} alkyl groups, the two alkyl groups may combine together to form an alkylene chain, or the carbocyclic or heterocyclic group may be a bicyclic group condensed with another saturated or unsaturated five- to seven-membered carbocyclic or heterocyclic ring;

one or two hydrogen atoms on the amino group, which may be represented by R^1, R^2, and R^3, are optionally substituted by C_{1-6} alkyl which is further optionally substituted by hydroxyl or C_{1-6} alkoxy;

R^4 represents a hydrogen atom;

all of R^5, R^6, R^7, and R^8 represent a hydrogen atom, or any one or two of R^5, R^6, R^7, and R^8 represent a halogen atom, C_{1-4} alkyl, C_{1-4} alkoxy, nitro, or amino with all the remaining groups representing a hydrogen atom, and

R^9 represents C_{1-4} alkyl substituted by a substituent selected from the group consisting of a saturated three- to seven-membered carbocyclic group; i-propyl optionally substituted by hydroxyl; t-butyl optionally substituted by hydroxyl; C_{1-4} alkoxy; and $-NR^aR^b$ wherein R^a and R^b, which may be the same or different, represent a hydrogen atom or C_{1-4} alkyl optionally substituted by hydroxyl, or R^a and R^b may combine with a nitrogen atom attached thereto to form a saturated five- or six-membered heterocyclic group, or R^9 represents a saturated five- to seven-membered carbocyclic group optionally substituted by one to three C_{1-4} alkyl groups.

Claim 19 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 1, wherein said compound represented by formula (I) is represented by formula (Ia):



(Ia)

wherein

X represents CH or N,

Z represents O or S,

R^{101} and R^{104} represent a hydrogen atom,

R^{102} and R^{103}, which may be the same or different, represent

a hydrogen atom,

hydroxyl,

a halogen atom,

nitro,

cyano,

$-NR^{111}R^{112}$ wherein R^{111} and R^{112}, which may be the same or different, represent a hydrogen atom or C_{1-4} alkyl,

$-(C=O)OR^{113}$ wherein R^{113} represents a hydrogen atom or C_{1-4} alkyl,

$-(C=O)NR^{114}R^{115}$ wherein R^{114} and R^{115}, which may be the same or different, represent a hydrogen atom or C_{1-4} alkyl,

C_{1-6} alkoxy,

C_{1-6} alkyl,

C_{1-6} alkenyl, or

C_{1-6} alkynyl,

the C_{1-6} alkoxy, C_{1-6} alkyl, C_{1-6} alkenyl, or C_{1-6} alkynyl are optionally substituted by hydroxyl; a halogen atom; C_{1-4} alkoxy; $-NR^{116}R^{117}$ wherein R^{116} and R^{117}, which may be the same or different, represent a hydrogen atom or C_{1-4} alkyl and the alkyl group is further optionally substituted by hydroxyl or C_{1-4} alkoxy; or a saturated or unsaturated three- to eight-membered carbocylic or heterocyclic group in which the cyclic group is optionally substituted by hydroxyl, a halogen atom, C_{1-4} alkyl, or C_{1-4} alkoxy,

all of R^{105}, R^{106}, R^{107}, and R^{108} represent a hydrogen atom, or any one or two of R^{105}, R^{106}, R^{107}, and R^{108} represent hydroxyl, C_{1-4} alkyl, C_{1-4} alkoxy, amino, nitro, or a halogen atom with all the remaining groups representing a hydrogen atom,

R^{109} represents $-(CH_2)n-R^{110}$ wherein n is 2, 3, or 4, and R^{110} represents i-propyl optionally substituted by C_{1-4} alkyl, C_{1-4} alkoxy, or hydroxyl; t-butyl optionally substituted by

C_{1-4} alkyl, C_{1-4} alkoxy, or hydroxyl; or a three- to nine-membered saturated carbocyclic group optionally substituted by C_{1-4} alkyl, C_{1-4} alkoxy, or hydroxyl.

Claim 20 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 19, wherein R^{102} and R^{103}, which may be the same or different, represent C_{1-6} alkoxy and the C_{1-6} alkoxy is optionally substituted by hydroxyl; a halogen atom; C_{1-4} alkoxy; -$NR^{116}R^{117}$ wherein R^{116} and R^{117}, which may be the same or different, represent a hydrogen atom or C_{1-4} alkyl and the alkyl group is further optionally substituted by hydroxyl or C_{1-4} alkoxy; or a saturated or unsaturated three- to eight-membered carbocylic or heterocyclic group in which the cyclic group is optionally substituted by hydroxyl, halogen atom, C_{1-4} alkyl, or C_{1-4} alkoxy.

Claim 21 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 20, wherein R^{102} and R^{103}, which may be the same or different, represent C_{1-6} alkoxy in which the alkoxy group is optionally substituted by a saturated or unsaturated three- to eight-membered carbocylic or heterocyclic group and the cyclic group is further optionally substituted by hydroxyl, a halogen atom, C_{1-4} alkyl, or C_{1-4} alkoxy.

Claim 22 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 21, wherein R^{102} and R^{103}, which may be the same or different, represent C_{1-4} alkoxy in which the alkoxy group is optionally substituted by a saturated five- to seven-membered heterocyclic group and the cyclic group is further optionally substituted by C_{1-4} alkyl.

Claim 23 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 22, wherein said substituted C_{1-4} alkoxy group is a group represented by



n=2, 3, 4

Claim 24 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 23, wherein n is 2.

Claim 25 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 22, wherein said substituted C_{1-4} alkoxy group is a group represented by



n=2, 3, 4

Claim 26 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 25, wherein n is 2.

Claim 27 (Currently Amended): The ~~pharmaceutical composition~~ method according to ~~any one of claims 19 to 26~~ claim 19, wherein one of R^{102} and R^{103} represents unsubstituted C_{1-6} alkoxy and the other represents substituted C_{1-6} alkoxy.

Claim 28 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 27, wherein R^{102} represents unsubstituted C_{1-6} alkoxy and R^{103} represents substituted C_{1-6} alkoxy.

Claim 29 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 28, wherein R^{102} represents methoxy.

Claim 30 (Currently Amended): The ~~pharmaceutical composition~~ method according to ~~any one of claims 19 to 29~~ claim 19, wherein X represents CH.

Claim 31 (Currently Amended): The ~~pharmaceutical composition~~ method according to ~~any one of claims 19 to 30~~ claim 19, wherein Z represents O.

Claim 32 (Currently Amended): The ~~pharmaceutical composition~~ method according to ~~any one of claims 19 to 31~~ claim 19, wherein all of R^{105}, R^{106}, R^{107}, and R^{108} represent a hydrogen atom, or any one or two of R^{105}, R^{106}, R^{107}, and R^{108} represent C_{1-4} alkyl, C_{1-4} alkoxy, or a halogen atom with all the remaining groups representing a hydrogen atom.

Claim 33 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 32, wherein R^{105} represents methoxy and R^{106}, R^{107}, and R^{108} represent a hydrogen atom.

Claim 34 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 32, wherein R^{105} represents methyl and R^{106}, R^{107}, and R^{108} represent a hydrogen atom.

Claim 35 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 32, wherein R^{105} represents a halogen atom and R^{106}, R^{107}, and R^{108} represent a hydrogen atom.

Claim 36 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 35, wherein the halogen atom represents a chlorine or fluorine atom.

Claim 37 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 35, wherein the halogen atom represents a fluorine atom.

Claim 38 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 32, wherein all of R^{105}, R^{106}, R^{107}, and R^{108} represent a hydrogen atom.

Claim 39 (Currently Amended): The ~~pharmaceutical composition~~ method according to any ~~one of claims 19 to 38~~ claim 19, wherein R^{109} is a group represented by



n=2, 3, 4

Claim 40 (Currently Amended): The pharmaceutical composition according to claim 39, wherein n is 2.

41. The ~~pharmaceutical composition~~ method according to ~~any one of claims19 to 38~~ claim 19, wherein R^{109} is a group represented by



n=2, 3

Claim 42 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 41, wherein n is 2.

Claim 43 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 19, wherein the compound represented by formula (Ia) is 1-(3,3-dimethyl-butyl)-3-{3-fluoro-4-[6-methoxy-7-(2-piperidin-1-yl-ethoxy)-quinolin-4-yloxy]-phenyl}-urea.

Claim 44 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 19, wherein the compound represented by formula (Ia) is 1-(2-cyclopentyl-ethyl)-3-{3-fluoro-4-[6-methoxy-7-(2-piperidin-1-yl-ethoxy)-quinolin-4-yloxy]-phenyl}-urea.

Claim 45 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 19, wherein the compound represented by formula (Ia) is 1-(2-cyclopentyl-ethyl)-3-{2-fluoro-4-[6-methoxy-7-(2-piperidin-1-yl-ethoxy)-quinolin-4-yloxy]-phenyl}-urea.

Claim 46 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 1, wherein the compound represented by formula (I) is represented by formula (II):



(II)

wherein

R^{15} and R^{16}, which may be the same or different, represent -O-(CH_2)r-R^{22} wherein r is an integer of 0 to 6, -(CH_2)r- is optionally substituted by C_{1-6} alkyl, hydroxyl, or a halogen atom, and R^{22} represents a hydrogen atom; hydroxyl; a halogen atom; C_{1-6} alkoxy; C_{1-6} alkylcarbonyl; carboxyl; C_{1-6} alkoxycarbonyl; -(C=O)-$NR^{23}R^{24}$ wherein R^{23} and R^{24}, which may be the same or different, represent a hydrogen atom or C_{1-4} alkyl optionally substituted by hydroxyl, or R^{23} and R^{24} may combine with a nitrogen atom attached thereto to form a saturated five- or six-membered heterocyclic group; amino in which one or two hydrogen atoms on the amino group are optionally substituted by C_{1-6} alkyl or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, and the C_{1-6} alkyl group is further optionally substituted by hydroxyl, C_{1-6} alkoxy, or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group; or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group in which the carbocyclic or heterocyclic group is optionally substituted by hydroxyl, an oxygen atom, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkoxycarbonyl, or a saturated or unsaturated three- to

eight-membered carbocyclic or heterocyclic group, the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl groups are further optionally substituted by hydroxyl, C_{1-6} alkoxy, or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, and, when the carbocyclic or heterocyclic group is substituted by two C_{1-6} alkyl groups, the two alkyl groups may combine together to form an alkylene chain, or the carbocyclic or heterocyclic group may be a bicyclic group condensed with another saturated or unsaturated five- to seven-membered carbocyclic or heterocyclic ring,

all of R^{17}, R^{18}, R^{19}, and R^{20} represent a hydrogen atom, or any one or two of R^{17}, R^{18}, R^{19}, and R^{20} represent a halogen atom, C_{1-4} alkyl, C_{1-4} alkoxy, nitro, or amino with all the remaining groups representing a hydrogen atom, and

R^{21} represents $-(CH_2)t-R^{61}$ wherein t is an integer of 1 to 4 and R^{61} represents a saturated three- to seven-membered carbocyclic group; i-propyl optionally substituted by hydroxyl; t-butyl optionally substituted by hydroxyl; C_{1-4} alkoxy; or $-NR^{62}R^{63}$ wherein R^{62} and R^{63}, which may be the same or different, represent a hydrogen atom, or C_{1-4} alkyl optionally substituted by hydroxyl, or R^{62} and R^{63} may combine with a nitrogen atom attached thereto to form a saturated five- or six-membered heterocyclic group, or R^{21} represents a saturated five- to seven-membered carbocyclic group optionally substituted by one to three C_{1-4} alkyl groups.

Claim 47 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 46, wherein R^{15} and R^{16} represent $-O-(CH_2)r-H$ wherein r is an integer of 1 to 4 and the $-(CH_2)r-$ part is unsubstituted, or any one of R^{15} and R^{16} ~~repersents~~ represents $-O-(CH_2)r-H$ wherein r is an integer of 1 to 4 and the $-(CH_2)r-$ part is unsubstituted with the other representing $-O-(CH_2)r-R^{22}$ wherein r is an integer of 1 to 4, the $-(CH_2)r-$ part is

unsubstituted, and R^{22} represents optionally substituted amino or an optionally substituted saturated three- to eight-membered heterocyclic group,

all of R^{17}, R^{18}, R^{19}, and R^{20} represent a hydrogen atom, or any one or two of R^{17}, R^{18}, R^{19}, and R^{20} represent a halogen atom, C_{1-4} alkyl, C_{1-4} alkoxy, nitro, or amino with all the remaining groups representing a hydrogen atom, and

R^{21} represents $-(CH_2)t-R^{61}$, wherein t is an integer of 1 to 4 and R^{61} represents a saturated five- to seven-membered carbocyclic group; i-propyl; t-butyl optionally substituted by hydroxyl; C_{1-4} alkoxy; or $-NR^{62}R^{63}$ wherein R^{62} and R^{63}, which may be the same or different, represent C_{1-4} alkyl, or R^{21} represents a five- to seven-membered carbocyclic group optionally substituted by 1 to 3 C_{1-4} alkyl groups.

Claim 48 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 46, wherein R^{15} and R^{16} represent $-O-(CH_2)r-H$ wherein r is an integer of 1 to 4 and the $-(CH_2)r-$ part is unsubstituted, or any one of R^{15} and R^{16} represents $-O-(CH_2)r-H$ wherein r is an integer of 1 to 4 and the $-(CH_2)r-$ part is unsubstituted with the other representing $-O-(CH_2)r-R^{22}$ wherein r is an integer of 1 to 4, the $-(CH_2)r-$ part is unsubstituted, and R^{22} represents optionally substituted amino or an optionally substituted saturated three- to eight-membered heterocyclic group,

all of R^{17}, R^{18}, R^{19}, and R^{20} represent a hydrogen atom; or R^{18} represents a fluorine atom, and R^{17}, R^{19}, and R^{20} represent a hydrogen atom; or R^{17} represents a halogen atom, C_{1-4} alkyl, or C_{1-4} alkoxy, and R^{18}, R^{19}, and R^{20} represent a hydrogen atom; or R^{17} and R^{19} represent a halogen atom, C_{1-4} alkyl, or C_{1-4} alkoxy, and R^{18} and R^{20} represent a hydrogen atom, and

R^{21} represents -(CH_2)t-R^{61}, wherein t is an integer of 2 or 3 and R^{61} represents a saturated five- to seven-membered carbocyclic group or t-butyl, or R^{21} represents a five- to seven-membered carbocyclic group optionally substituted by one to three C_{1-4} alkyl groups.

Claims 49-50 (Canceled).

Claim 51 (Original). A compound represented by formula (Ia) or a pharmaceutically acceptable salt or solvate thereof:



(Ia)

wherein X, Z, R^{101}, R^{102}, R^{103}, R^{104}, R^{105}, R^{106}, R^{107}, R^{108}, and R^{109} are as defined in claim 19.

Claim 52 (Original): A compound represented by formula (II) or a pharmaceutically acceptable salt or solvate thereof:



(II)

wherein R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, and R^{21} are as defined in claim 46.

Claim 53 (Original): A pharmaceutical composition comprising a compound according to claim 51 or 52 or a pharmaceutically acceptable salt or solvate thereof.